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Highlights: 
 Cimicifuga heracleifolia and Arnebia euchroma extracts inhibited in vitro EV-A71 infection.  
 By a combined effort of bioassay-guided purification, high-resolution mass spectrometry and NMR, we identified active peaks from the 
plant extracts.  
 Fukinolic acid and cimicifugic acid A/J and caffeic acid derivatives were deduced as Cimicifuga heracleifolia and Arnebia euchroma, 
active compounds, respectively.  
 Fukunolic acid derivatives, L- and D-chicoric acid, showed activity in the low micromolar range against EV-A71 clinical isolates. 
 
 
 
 
 
 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
Title: Identification of fukinolic acid from Cimicifuga heracleifolia and its derivatives as novel antiviral compounds against enterovirus A71 
infection. 
 
Authors  
Yipeng Ma
a,b
 , Wenjuan Cong
c
 , Hao Huang
d
 , Liang Sun
a
, Anh Hung Mai
e
, Kurt Boonen
b
, Wahedi Maryam
f
, Wim De Borggraeve
g
, Guoan Luo
h
 
, Qingfei Liu
i
 , Liliane Schoofs
b
 , Frank Van Kuppeveld
f
, Johan Neyts
a
, Carmen Mirabelli
a
 , Walter Luyten
b,*
 
 
a
 Laboratory of virology and chemotherapy, Rega institute for medical research, KU Leuven, Belgium 
b
 Laboratory of animal physiology and neurobiology, Department of Biology, KU Leuven, Belgium 
c
 Wolfson Wohl Cancer Research Centre, University of Glasgow, UK  
d
 College of Pharmacy, Gannan Medical University, Ganzhou, China  
e
 R&D Department, PolymerExpert,1 Allée du Doyen Georges Brus, Pessac, France 
f
 Departement of infection and immunology, University of Utrecht, the Netherlands  
g
 Molecular Design and Synthesis unit, Chemistry department, KU Leuven, Belgium   
h
 Department of Chemistry, Tsinghua University, Beijing, China  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
i
 School of Medicine, Tsinghua University, Beijing, China  
 
 
 
*
Corresponding author:  
Prof Walter Luyten  
Naamsestraat 59, 3000 Leuven, Belgium.  
Email address: walter.luyten@kuleuven.be 
 
 
 
 
 
 
Abstract 
Human enterovirus 71 (EV-A71) infections cause a wide array of diseases ranging from diarrhoea and rashes to hand-foot-and-mouth disease 
and, in rare cases, severe neurological disorders. No specific antiviral drug therapy is currently available. Extracts from seventy-five Chinese 
medicinal plants selected for antiviral activity based on the Chinese pharmacopeia and advice from traditional Chinese medicine clinicians were 
tested for activity against EV-A71. The aqueous extract of the rhizome of Cimicifuga heracleifolia (Sheng Ma) and Arnebia euchroma (Zi Cao) 
showed potent antiviral activity. The active fractions were isolated by bioassay-guided purification, and identified by a combination of high-
resolution mass spectrometry and NMR. Fukinolic acid and cimicifugic acid A and J, were identified as active anti-EV-A71 compounds for 
Cimicifuga heracleifolia, whereas for Arnebia euchroma, two caffeic acid derivatives were tentatively deduced. Commercially available 
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fukinolic acid analogues like L-chicoric acid and D-chicoric also showed in vitro micromolar activity against EV-A71 lab-strain and clinical 
isolates. 
 
 
 
Key words: Cimicifuga heracleifolia; Arnebia euchroma; fukinolic acid; cimicifugic acid; enterovirus 71; traditional Chinese medicine 
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Introduction 
Enterovirus 71 (EV-A71) belongs to the genus Enterovirus of the family Picornaviridae, small viruses characterized by a naked icosahedral 
capsid and a positive-sense, single-stranded RNA. EV-A71 is the causative agent of hand-foot-and-mouth disease (HFMD), but other clinical 
manifestations associated with EV-A71 infection range from skin rashes and herpangina to brain stem encephalitis [1]. Recurrent EV-A71 
epidemics of various scales have occurred in the Asia-Pacific region [2, 3]. Because of its marked neurotropism, following the near complete 
eradication of poliovirus, EV-A71 may become the greatest threat amongst enteroviruses to cause significant neurological complications [4]. An 
inactived EV-A71 vaccine has been approved in China in 2015 for prevention of HFMD [5]. In view of the rapid recombination of EV-A71, the 
absence of cross-reactivity among EV-A71 sub-genogroups and the emergence of new genotypes [6, 7], it is not clear whether monovalent 
vaccines will offer sufficient protection [8]. Moreover, related enteroviruses can cause HFMD, although EV-A71 is the most pathogenic [8]. The 
main driver for vaccine development has been the lack of an effective antiviral drug. Antiviral drugs are urgently needed to prevent EV-A71 
epidemics [9], and drug development has been underway for over a decade [10, 11], targeting various stages of the viral life cycle [12, 13]. 
There is evidence that some traditional Chinese medicines (TCMs) may be beneficial for the treatment of viral infections, including EV-A71 
[14]. Therefore, we decided to test a range of TCM plants for anti-EV-A71 activity. Here, we report the identification of novel anti-EV-A71 
compounds from the rhizome of Cimicifuga heracleifolia (Sheng Ma) and from Arnebia euchroma (Zi Cao).  
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2. Materials and methods 
2.1 Chemicals and compounds 
Acetonitrile of HPLC grade, ethanol and acetone of analytical grade were purchased from Sigma-Aldrich Co. (Belgium). Hexane of analytical 
grade was purchased from Acros Co. (Belgium). Sterile deionized water was produced by a water purification system (Milli-Q Reagent Water 
System, MA, USA). Rosmarinic acid, L-chicoric acid, D-chicoric acid, salvianolic acid A hydrate, salvianolic acid B, 1,3-dicaffeoylquinic acid, 
chlorogenic acid and caftaric acid were purchased from Sigma-Aldrich Co. (Belgium).  
2.2 Preparation of plant extracts, fractions and compounds 
Cimicifuga heracleifolia root and Arnebia euchroma were purchased from a certified TCM vendor: Tongrentang Pharm. Co. Ltd. (Beijing, 
China, http://www.tongrentang.com/en/). The plant material was ground to a fine powder and small-scale extracts were prepared as described 
before [15]. One gram of plant powder was used in the small-scale extracts. For a large-scale aqueous extract, 100 g of plant powder was 
transferred into a 1000 mL flask, and sterile deionized water was added in a w/v ratio of 1/10. The flask was then kept at ambient temperature 
and placed in a bath sonicator for 4 times 15 min each, with an interval of 6 hours.  The extract was then centrifugated at 1800 rpm for 8 min. 
The supernatant was filtered through MN615 185 mm filter paper, transferred into a round-bottom flask and dried in a rotary evaporator (Heto 
Rotavapor-R). The same volume of fresh deionized water was added to the plant material to start another extraction cycle. A total of three 
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successive extraction cycles was completed. The dried pooled aqueous extract was then separated on a preparative HPLC column (PrepPak C18, 
15 µm, 40x100mm) using acetonitrile/water as mobile phase, whereby the acetonitrile concentration increased linearly to 100%. The elution 
flow rate was 40 mL/min and controlled by a Waters 600 controller and monitored by a Waters 2487 Dual λ Absorbance Detector at 214 nm and 
280 nm. Active compounds were obtained by activity-guided purification. Briefly, active fractions from the preparative HPLC column were 
separated further using a Sunfire semi-prep C18 column (reversed-phase, 5 µm, 4.6 x 150 mm) with an injection loop of 2 mL on a Shimadzu 
DGU0A3 system, equipped with a diode array detector monitoring from 190 to 800 nm, and using a gradient elution at a flow rate of 4 mL/min 
starting with acetonitrile/water at 10%. The HPLC column was washed with 100% acetonitrile for 10 min after each run. 
2.3 Mass spectrometry 
The analysis was performed on a Q Exactive orbitrap mass spectrometer (Thermo Scientific, San Jose, CA). The mass spectrometer was coupled 
online to an Ultimate 3000 ultra-high performance liquid chromatography (UHPLC) instrument (Thermo Scientific, San Jose, CA). The UHPLC 
system was equipped with a 2 µm particle size, 10 nm pore size Easy Spray Pepmap RSLC C18 column with dimensions 50 µm x 15 cm 
(Thermo Scientific, San Jose, CA). Before sample separation on the analytical column, the lyophilized sample was dissolved in 16 µL of a 2% 
acetonitrile/0.1% aqueous formic acid (FA) solution. A needle voltage of 1.5 kV and a capillary temperature of 25°C were applied. Next, a 5 µL 
sample was injected and put on-line with a 3 µm particle size, 10 nm pore size, nanoviper, Acclaim Pepmap 100 C18 precolumn of dimensions 
75 µm x 2 cm (Thermo Scientific, San Jose, CA). Sample separation was performed using a 30 min gradient of 0.1% aqueous FA (solvent A) 
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and 80 % acetonitrile, 0.08 % aqueous FA (solvent B) and a flow-rate of 300 nL/min. The percentage of solvent B increased from 4 % to 70 % 
in 30 min and was followed by a steep increase to 95 % in 2 min. An inherent rinse step (2 min gradient, from 4 % to 95 % and 3 min rinsing at 
95% solvent B) was applied after every run. The Q Exactive mass spectrometer was operated in data-dependent mode. Mass spectra were 
acquired alternately in the positive and negative ionization mode with an m/z scan range of 100 to 1500 m/z. For each precursor spectrum, up to 
the ten of the most intense ions were selected for the generation of fragmentation spectra. For precursor spectra, a resolving power of 140,000 
full width at half maximum (FWHM) was used with an automatic gain control (AGC) target of 3,000,000 ions and a maximum ion injection 
time (IT) of 100 msec. For fragmentation spectra, a resolving power of 17,500 FWHM, an AGC target of 1,000,000 ions, an isolation window of 
3 m/z, a fixed first mass of 50 m/z and a maximum IT of 256 msec were used. Dynamic exclusion of 10 sec was applied in order to avoid 
repeated fragmentation of the most abundant ions. Concerning ion selection, only singly-charged ions were selected. From high-accuracy 
masses, compatible chemical formulae were deduced using ChemCalc [16]. Exact (mono-isotopic) masses or chemical formulae were then used 
to search databases like Chemspider or Universal Natural Products Database [17] for natural products with these properties. We tentatively 
identified several compounds by comparing with the published MS/MS profile list in [18-21]. 
2.4 NMR  
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The structure of purified compounds was solved by NMR as described before [22]. Briefly, NMR spectra were recorded on 400 MHz and 600 
MHz FT-NMR spectrometers in the deuterated solvents and at temperatures indicated in table 2; chemical shifts are expressed in scale (ppm) 
using tetramethylsilane as an internal standard, and coupling constants J are in Hertz (Hz). 
 
 
2.5 Antiviral test against EV-A71 
Dried extracts or fractions were dissolved in DMSO and tested in a cell-based assay with live enteroviruses as described before [23]. Briefly, RD 
cells [24], grown for 3-4 days in 150 cm² tissue culture flasks were harvested and seeded in MEM Rega 3 medium (Gibco) supplemented with 
2% fetal bovine serum (FBS) (Integro), 1% 200 mM L-glutamine (Gibco) and 1% 7.5% NaHCO3 (Gibco) at a density of 25,000 cells/well in 96-
well plates. The microtitre plates were incubated overnight, yielding a non-confluent cell monolayer. Subsequently, the assay plates were 
transferred to a liquid handling platform on which a sample dilution series was prepared starting at a sample concentration of 100 µg/mL or 
lower, if necessary. Following preparation of the compound dilution series, virus was added to the wells with a dilution optimized for each EV-
A71 strain. The final, maximal DMSO concentration that was reached in the assay wells with the highest sample input (1%) was well tolerated 
by the cells. The assay plates were returned to the incubator at 37 ℃ for 4 days, at which time the untreated, virus-infected condition (virus 
controls, VC) showed 100% virus-induced cell death while in the untreated, uninfected condition (cell controls, CC) a perfectly healthy cell 
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monolayer could be observed. For quantification of the antiviral and anti-metabolic effect of the samples, the assay medium was replaced with 
100 µL of a 5% MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenol)-2-(4-sulfophenyl)-2H-tetrazolium, innersalt) (Promega) 
solution in phenol red-free medium and incubated for 1.5 hours. OD values were recorded with a microtitre plate reader (Safire², Tecan) and 
uploaded on a custom-designed database-coupled data processing platform (Accelrys) for further processing and quality control.  
 
 
2.6 Protease assay  
A 3C protease assay was performed as previously described [25]. Briefly, COS-1 cells at a concentration of 0.5 x 10
5
 cells/mL, were seeded in a 
96-well plate in 100 µl Dulbecco's Modified Eagle's medium (DMEM). The next day, the cells were co-transfected in triplicate using Fugene 
with 100 ng/well of a construct containing the viral 3C protease-coding region between a Gal4-binding domain and a VP16-activation domain 
and 100 ng/well of plasmid containing Gal4-sequences upstream of a luciferase reporter under the control of VP16. Two hours after transfection, 
the cells were treated with DMSO or fukinolic acid-containing medium prepared as a three-fold serial dilution. A rupintrivir-analogue was used 
as positive control of anti-3C protease activity. After 16 hours post transfection, the medium was removed and the cells were washed with 
Phosphate-buffered saline (PBS) and lysed in 20 µL Passive Lysis Buffer (Promega) for 30 min at room temperature. The luciferase activity was 
then measured using the Dual-Glo Luciferase Assay System (Promega) and recorded whenever the 3C-protease activity was affected by the 
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compound treatment. Therefore, luciferase signal represents, in this assay, a measure of the anti-protease (and in turn antiviral) activity of the 
selected compounds.   
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3. Results 
3.1 The aqueous extract of Cimicifuga heracleifolia and Arnebia euchroma inhibits EV-A71 replication in vitro 
Over seventy-five plants listed in the Chinese Pharmacopeia were selected on the basis of previously reported antiviral activity [26]. Small-scale 
extracts were prepared from 1 g of botanical material in 10 mL of four different solvents: water, ethanol, acetone and hexane. These extracts 
were tested in a cell-based antiviral assay to evaluate the in vitro antiviral activity against EV-A71. The requirement for the extract to be a true 
selective inhibitor of EV-A71 replication was the complete protection of the cells from virus-induced cell death for at least one concentration, 
without causing any significant alteration of cell monolayer morphology as compared to the untreated, uninfected cell control condition. Among 
the extract tested, Cimicifuga heracleifolia aqueous extracts showed strong antiviral activity, together with low levels of cytotoxicity. The EC50 
was approximately 17 µg/mL and the EC90 was 66 µg/mL. Aqueous extracts of Arnebia euchroma showed an even more potent activity against 
EV-A71, with EC50 and EC90 of 1.6 µg/mL and 5.7 µg/mL, respectively. 
3.2 Identification of active fractions by bioassay-guided purification 
A large-scale aqueous extract of Cimicifuga heracleifolia was prepared as described in materials and methods. The extract was fractionated on a 
preparative C18 column. Fractions 25-30, 32-33 and 35-40 showed strong anti-EV-A71 activity (Figure 1). In particular, EC50s of fractions 28 
and 33 were quite low: around 6.9 and 1.5 µg/mL, respectively. Fractions 28 and 33 were therefore further separated (Figure 1) and tested for 
anti-EV-A71 activity. Based on the correspondence between active fractions and chromatographic peaks (Figure 1), presumptive active peaks 
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were collected and their antiviral activity was confirmed. A large-scale aqueous extract of Arnebia euchroma was also prepared using the same 
method. Fractions 34-37, 39-41 and 45-56 showed potent activity against EV-A71 (Figure 2). Particularly, fraction 37 and 39 had an EC50 of 7.1 
µg/mL and 8.5 µg/mL, respectively. The fractions were further separated using semi-preparative HPLC on a C18 column (Figure 2), and peaks 
were collected for antiviral testing. 
3.3 Fukinolic acid and cimicifugic acid A and J are novel anti-EV-A71 compounds  
The antiviral profile of the peaks from fraction 28 of Cimicifuga heracleifolia revealed that peak 15 and 16 (F28P15, F28P16) carried the anti-
EV-A71 activity with EC50 of 28 and 4.3 µg/mL, respectively. Peak 11-14 were isolated from fraction 33 but only the 11 and 13 showed activity 
(F33P11, F33P13) with EC50s of about 20 µg/mL. After the bioassay-guided purification of the peaks, we wanted to identify the active 
compounds in each fraction, by means of high-resolution mass spectrometry and NMR. F28P16 was identified as fukinolic acid (Figure 3), first 
by LC-MS/MS and then further confirmed by NMR (table 1 and S1). F28P15 was tentatively identified to have a chemical formula of C22H22O11 
and, based on a similar fragmentation pattern than sinapinic acid in MS/MS, it was suggested to be cimicifugic acid J (table 1). Based on MS 
data, F33P11 had a probable formula of C22H22O12 and was identified as cimicifugic acid I by MS/MS and proton NMR. F33P13 was tentatively 
identified to have a formula of C21H20O11 and showed the same fragmentation pattern as cimicifugic acid A/B (table 1). A proton NMR was 
performed to confirm F33P13 as cimicifugic acid A. Interestingly, the adjacent peak 14 (F33P14), which did not show activity against EV-A71, 
was identified on the basis of MS/MS and proton NMR as cimicifugic acid B. We were unable to identify F33P11. 
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Active peaks from Arnebia euchroma fraction 37 were peak 3 and 4 (F37P3 and F37P4) with EC50 of 12 and 6 µg/mL, respectively: and peak 3 
and peak 6 were the active peaks from fraction 39 (F39P3 and F39P6) with EC50 of 20 and 9 µg/mL, respectively. Based on MS/MS 
fragmentation patterns, F37P3 was expected to be a caffeic acid derivative. According to the proposed formula (C27H22O12), the active 
compound could be lithospermic acid, salvianolic acid H/I, or salvianolic acid J (table 1). The presumptive formula of F39P6 (C36H30O16) was 
also deduced from MS. We were unable to get the MS/MS spectrum of F39P6 in negative ion mode, but its positive ion mode MS/MS spectrum 
was highly similar to F37P3, which suggests that F39P6 may be a conjugate of F37P3, possibly salvianolic acid B, salvianolic acid E or 
salvianolic acid L. We could not identify F37P6 and F39P.  
3.4 Antiviral activity and SAR of fukinolic and caffeic acid derivatives  
In order to confirm the bioassay-guided purification and the identification of active compounds, we obtained fukinolic acid and caffeic acid 
derivatives from commercial sources: L- and D-chicoric acid, rosmarinic acid and salvianolic acid A and B. A cell-based antiviral assay was 
performed with serial dilution of the purchased compounds in RD cells to confirm/assess their antiviral activity. The results are summarized in 
table 2. For the fukinolic acid derivatives L- and D-chicoric acid, the activity observed in the active fractions was more pronounced than that 
observed for the purchased compounds. Salvianolic acid A showed activity in a low µM range, in agreement with a recent publication [27]. By 
comparing the antiviral activities of the active compounds, we could also deduce some SAR indications. Cimicifugic acid B was the only 
tentatively identified compound not active in vitro against EV-A71. The hydroxyl group at position R2 is thus crucial for antiviral activity (Table 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
2). In opposition, the hydroxyl group at position R1 is less critical for activity, since the methylation of R1 (cimicifugic acid A) decreased the 
EC50 about 5-fold only. The addition of a hydroxymethyl group at position R3 (cimicifugic acid I) also resulted in loss of activity. Ultimately, 
although cimicifugic acid J shares the same R groups as cimicifugic acid I, it showed some activity against EV-A71 suggesting that the 
substituents in the opposite benzyl play also a role in the activity of this class of compounds.  
3.5 Fukinolic and caffeic acid analogues showed potent antiviral activity against EV-A71 clinical isolates 
In order to explore the clinical relevance of our findings, we wanted to assess the activity of the aforementioned fukinolic and caffeic derivatives 
in the context of EV-A71 clinical isolates infection. Indeed, the lab-adapted strain BrCr used for the previous experiment is poorly representative 
of the circulating EV-A71. For instance, clinically relevant genogroup B and C were used in this experiment to infect RD cells in the presence of 
serial dilution of compounds. Pirodavir, a capsid binder, was used as a reference compound. Overall, all the tested derivatives showed a potent 
activity, in a low micromolar range, against EV-A71 clinical isolates with an improvement up to 50x compared to the activity against the lab-
adapted BrCr strain (table 3). The antiviral activity of fukinolic and caffeic acid derivatives was also assessed in the context of non-EV-A71 
enteroviruses (rhinovirus B14 and coxsackievirus B3) and non-enteroviruses infection (Zika virus and Chikungunya virus). The compounds 
proved inactive against all tested viruses, suggesting that these compounds are selective inhibitors of EV-A71 replication.  
3.6 Inhibition of 3C protease activity  
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Fukinolic acid and cimicifugic acid J have been previously described to inhibit (carboxyl) peptidases [28]. We therefore wanted to assess the 
effect of fukinolic acid on the activity of the 3C viral peptidase. We hypothesized that the anti-protease activity could explain the antiviral effect 
of fukinolic acid and its analogues on EV-A71 replication. A 3C protease activity assay was performed by co-transfecting COS-1 cells with a 
construct encoding the 3C protease gene flanked by a Gal4 binding domain and a VP16 domain and a luciferase construct with an upstream Gal4 
sequence and under the control of the VP16 domain [25]. Briefly, if the 3C protease is functional it will cleave, with its auto-catalytic domain, 
the Gal4BD and the VP16 domain and the luciferase reporter will become transcriptionally inactive (no luciferase signal). On the other hand, if 
the activity of the 3C protease is affected (by the compound treatment) the Gal4BD-3C-VP16 ORF will bind the Gal4 sequence on the luciferase 
reporter plasmid and the VP16 domain will recruit the RNA polymerase to start the transcription of the reporter (luciferase signal). Rupintrivir is 
a well described viral 3C protein inhibitor and a rupintrivir-analogue was used as positive control. Following co-transfection and treatment with 
serial dilution of the rupintrivir-analogue and the fukinolic acid, we detected an increased luciferase signal, i.e an increased anti-protease activity 
only following rupintrivir-analogue treatment (Figure 3). Fukinolic acid did not show any anti-protease activity suggesting that it inhibits viral 
replication with a different mechanism of action.   
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4. Discussion  
Cimicifuga heracleifolia has been used in the clinic to treat flu-like illness and sore throat for centuries [29]. Cimicifuga heracleifolia is also a 
component of Sheng-Ma-Ge-Gen-Tang (SMGGT), a popular complex prescription used to treat measles in children. SMGGT proved active also 
against EV-A71 in vitro [30]. Fukinolic acid and several cimicifugic acids were isolated from some Cimicifuga species before [31]. We reported 
here for the first time that fukinolic acid, as well as cimicifugic acid A and J are the anti-EV-A71 active compounds from Cimicifuga 
heracleifolia. We also evaluated the antiviral activity of fukinolic acid analogues against EV-A71 clinical isolates and we detected a remarkable 
improvement of antiviral activity as compared to the lab-adapted BrCr strain, emphasizing the clinical relevance of our findings. Fukinolic acid 
analogues like L-chicoric and D-chicoric acid, and dicaffeoylquinic acid were found to have anti-human immunodeficiency virus (HIV) 
integrase activity [32]. Since EV-A71 replication is purely cytoplasmic and does not rely on an integrase activity, the antiviral activity of the 
here-described class of compounds must be mechanistically distinct. We tested instead the anti-EV-A71-3C-protease activity of fukinolic acid in 
a cell-based 3C protease assay but the result of the assay was negative suggesting that this mechanism of action is unlike.  
Arnebia euchroma is a species of the Boraginaceae family, whose roots are often used to regulate blood circulation in TCM [33]. The extracts 
from plants of the Boraginaceae family have various biological activities like antifungal [34], antioxidant [33] and anti-HIV activities [35]. 
Caffeic acid analogues like rosmarinic acid and lithospermic acid were identified from plants of the Boraginaceae family before [36, 37], and 
also from Salvia miltiorrhiza [21], whose aqueous extract also shows activity against EV-A71 [38]. Rosmarinic acid, lithospermic acid and 
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lithospermic acid B have shown in vitro anti-HIV activity [39]. Moreover, it has been reported that rosmarinic acid, salvianolic acid A, 
salvianolic acid B and magnesium lithospermate B have anti-EV-A71 activity [27]. In this study, we confirmed these finding and we explore the 
activity of salvianolic acid in the context of infection by clinically-relevant EV-A71 strains. As previously mentioned, rosmarinic, lithospermic 
and various salvianolic acids (included A and B) were identified from Salvia miltiorrhiza (Danshen) before [21, 40] whose aqueous extract also 
shows activity against EV-A71 [38]. Danshen has been widely used in China for centuries. Many recent clinical trials of Danshen products 
support its safe use in humans [40] and Danshen Capsule has received marketing authorisation in The Netherlands as a herbal remedy
1
. 
Combined with our in vitro findings, these facts support the potential use of Danshen for the treatment of EV-A71-infected patients.  
Conclusion  
With a combined effort of bioassay-guided purification, high-resolution mass spectrometry and NMR, we identified the fractions of Cimicifuga 
heracleifolia and Arnebia euchroma responsible for anti-EV-A71 activity in vitro. For the first time, we described fukinolic acid, as well as 
cimicifugic acid A and J as inhibitors of EV-A71 replication. Moreover, we report a very pronounced activity of fukinolic acid derivatives (in 
the low micromolar range) in the context of EV-A71 clinical isolates infection. We also identified two caffeic acid derivatives as active 
compounds against EV-A71. Efforts to determine the precise mechanism of action of these classes of compounds are currently ongoing.   
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FIGURE LEGEND  
Figure 1. (a) The anti-EV-A71 activity-guided separation and purification of Cimicifuga heracleifolia fractions. Sixty fractions (F1-F60) were 
obtained and tested for activity against the EV-A71 BrCr strain. When at least at one concentration a fraction could fully inhibit the virus-
induced CPE without showing toxicity, the corresponding bar is marked in black (non-active fractions are depicted in gray). (b,c) HPLC 
chromatogram of fraction 28 and fraction 33. F28 and F33 were chosen for further purification on a semi-preparative C18 HPLC column using a 
gradient elution as indicated by the black line. Peaks were collected and tested for anti-EV-A71 activity. F28 peak 15, F28 peak 16, F33 peak 11 
and F33 peak 13 were active. EC50: concentration of compound at which the virus-induced cytopathic effect is reduced by 50%. Values are from 
one experiment. 
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Figure 2. (a) The anti-EV-A71 activity-guided separation and purification of Arnebia euchroma fractions. Sixty fractions (F1-F60) were 
obtained and tested for activity against the EV-A71 BrCr strain. When at least at one concentration a fraction could fully inhibit the virus-
induced CPE without showing toxicity, the fraction bar is marked in black (non-active fractions are depicted in red). (b,c) HPLC chromatogram 
of fraction 37 and fraction 40. F37 and F40 were chosen for further purification on a semi-preparative C18 HPLC column using a gradient 
elution as indicated by the black line. Peaks were collected and tested for anti-EV-A71 activity. F37 peak 3, F37 peak 4, F40 peak 3 and F40 
peak 6 were active. EC50: concentration of compound at which the virus-induced cytopathic effect is reduced by 50%. Values are from one 
experiment.  
 
Figure 3. Anti-EV-A71 3C protease activity of fukinolic acid. Cell-based EV-A71 3C protease assay was performed by co-transfecting a plasmid 
encoding for EV-A71 3C protease in combination with a pG5luc reporter plasmid. Fukinolic acid, rupintrivir-like (positive control) and DMSO 
(negative control) were added and after 24h, the luciferase levels were measured. The inhibition of protease activity was measured as an 
induction of FLuc expression and subsequent increase of luciferase signal. Experiments were performed in triplicate and values represent the 
mean ± SD of the three measurement. 
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Plant Peak [M-H]
-
 m/z 
[2M-H]
- 
m/z 
[M+H]
+
 
m/z 
[2M+H]
+
 
m/z 
HPLC-ESI-MS
2
 m/z 
(% base peak) 
Tentatively identified 
compounds 
EC
50
 ±SD 
(µg /mL) 
CC
50
±SD 
(µg /mL) 
C
im
ic
if
u
g
a
 h
e
ra
c
le
if
o
lia
 
F28P15 - - 463.1233 925.2380 MS
2
[463]: 224(1), 207(100), 175(27), 
147(3), 119(2), 91(1) 
Cimicifugic acid J
a
 27.7±1.1 >70 
F28P16 433.0763 867.1613 435.0922 869.1769 MS
2
[433]: 433(1), 271(98), 253(35), 
235(7),  209(3), 191(27), 179(100) 
Fukinolic acid
a,c
 4.3±0.1 50±0 
F33P11 - - - - - - 26.9±15.9 >100 
F33P12 477.1041 - 479.1159 957.2229 MS
2
[477]: 253(70), 223(10) 191(100), 
181(75), 165(50), 109(30) 
Cimicifugic acid I
c
 >100 >100 
F33P13 447.0920 - 449.1070 914.2378 MS
2
[447]:  447 (100),  253 (90), 
235(5), 191 (10), 181 (10) 
Cimicifugic acid A
a,c
 21.3±11 >100 
F33P14 447.0929 - 449.1068 914.2314 - Cimicifugic acid B
c
 >100 >100 
A
rn
e
b
ia
 e
u
c
h
ro
m
a
 
F37P3 537.0637 1075.1331 - - 
MS
2
[537]: 339(20), 295(23), 
269(22),228(23),  197(100), 179(55), 
135(95), 109(8) 
C
27
H
22
O
12
b 10.6±0.4 >90 
F37P4 - - - - - - 5.4±1.1 >100 
F39P3 - - - - - - 19.8±2.3 >100 
F39P6 717.0912 1435.1892 - - - C36H30O16
b 36.3±3.0 >100 
Table 1. Characterization by mass spectrometry and anti-EV71 activity of active peaks.  
a 
Identification by comparing with previous published report.  
b 
Identified as caffeic acid derivatives based on MS/MS fragmentation patterns. 
C 
Identification confirmed by NMR spectrum. 
 
EC
50
, concentration of compound at which the virus-induced cytopathic effect is reduced by 50%.  
CC
50
, concentration of compound at which a 50% reduction in cell viability is observed.  
EC
50
 and CC
50
 values were obtained from multiple independent (>1) experiments.  
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Table 2. Summary of compound structures and their activities against EV71 BrCr lab strain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Structures of 
tentatively 
identified 
compounds 
from 
Cimicifuga 
heracleifolia 
Name Core structure 
Fukinolic 
acid 
Cimicifugic 
acid J 
Cimicifugic 
acid I 
Cimicifugic 
acid A 
Cimicifugic 
acid B 
EC50 ±SD 
(µg /mL) 
/ 4.3±0.1 27.7±1.1 >100 21.3±11 >100 
Structure 
      
Structures of 
compounds 
obtained 
commercially 
Name L-Chicoric acid D-Chicoric acid 
Rosmarinic 
acid 
Salvianolic acid 
B 
Salvianolic acid A hydrate 
EC50 ±SD 
(µg /mL) 
55.5±10.8 60.7±7.4 21.9±2.1 55.5±11.1 3.6±0.2 
Structure 
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Table 3. Antiviral activity of commercially obtained compounds against EV71 BrCr and clinical isolates. 
 
 
 
 
 
 
 
 
 
 
 
 
EV71 
Genogroup 
Virus strain 
EC
50
 ±SD (µg /mL) 
L-Chicoric 
acid 
D-Chicoric 
acid 
Rosmarinic 
acid 
Salvianolic 
acid A 
Salvianolic 
acid B 
Pirodavir 
A BrCr 55.5±10.8 60.7±7.4 21.9±2.1 3.6±0.2 55.5±11.1 1.2±0.1 
B2 11316 9.0±0.4 9.1±0.9 3.2±0 0.7±0.1 3.0±0.5 0.2±0.02 
B5 TW/70902/08 10.6±2.6 8.3±0.4 3.8±0.1 1.1±0 4.3±0.3 0.2±0.02 
C2 H08300 461 7.6±0.8 8.4±0.1 3.9±0.1 0.9±0 1.1±0.2 0.3±0.03 
C4 TW/1956/05 8.4±0.2 8.4±0.1 2.2±0.1 1.1±0 2.1±0 0.2±0 
CC
50 
(µg /mL) >100 >100 56.4±7.1 25.5±7.4 86.4±7.6 >10 
